Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE014 (NLD) (Dr. Moreau)
· consented 2022-05-04
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-07-15 (study day 54); relationship: N
mild
assessed
2026-08-18
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-05 (study day 136); relationship: N
moderate
assessed
2026-08-18
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-11-18 (study day 180); relationship: N
moderate
assessed
2026-08-18
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 253); relationship: N
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-07-12 (study day 416); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-10 (study day 476); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.